Developer docs
API playgroundTry for free, no card

Search company profiles

Phantom Neuro

Full company profile

uuid0000atf

Namestring
Phantom Neuro
Legal namestring
Phantom Neuro Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Phantom Neuro is a clinical-stage neurotechnology company developing the Phantom X, a minimally invasive muscle-machine interface (MMI) that captures electrical signals from residual limb muscles through a subcutaneous implantable sensor and uses proprietary AI algorithms to decode movement intent in real-time for intuitive control of prosthetic limbs and robotic systems. Founded in 2020 by Connor Glass and headquartered in Austin, Texas, the platform has demonstrated 94% accuracy across 11 distinct hand and wrist movements in the ASCENT non-invasive validation study, with 10 minutes of calibration restoring up to 85% of hand and wrist functionality. The system is designed as a simple outpatient procedure—accessible to over 70,000 US practitioners—positioning it as a less invasive alternative to brain-computer interfaces for amputees.

The company is pursuing FDA regulatory approval and received both Breakthrough Device Designation and TAP Acceptance in 2025. Its first-in-human CYBORG Early Feasibility Study, approved in Australia in April 2026, will enroll up to 10 upper limb amputee participants over approximately 20 weeks at Cabrini Health in Melbourne, with prosthetic care provided by ProMotion Prosthetics and Enable Rehab. The Australian study is structured to support a future US FDA IDE submission and pivotal trial. Beyond prosthetics, Phantom Neuro is positioning its in-vivo movement data capture as a training asset for humanoid robotics and human-machine collaboration applications, with an active partnership with DARPA covering defense and exoskeleton use cases.

Phantom Neuro's business model is anchored on medical device hardware sales of the Phantom X system, with a secondary optionality around licensing its sensing platform and movement data to robotics companies. The company operates an enterprise medical device commercialization pathway—maintaining a community patient registry (registry.phantomneuro.com) for clinical trial recruitment, engaging in scientific publications, and leveraging its strategic partnership with Ottobock for distribution. Ottobock led the $19M Series A in April 2025 and holds a board seat, contributing global prosthetics commercialization expertise. The company has raised approximately $28M in total disclosed funding across seed, Series A, and non-dilutive DARPA support, with no commercial revenue to date.

Short descriptiontext

Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface using proprietary AI and subcutaneous sensors to decode muscle signals for intuitive prosthetic limb control. The Austin-based company, founded in 2020, targets amputees and is pursuing FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable neural interface, muscle-machine interface, prosthetic limb control, neural signal decoding, robotic rehabilitation devices
Industry3 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHSADAIAC
Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS)
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
SECONDARYHDAAAIAL
Robot Hardware, Actuators & Components (sensors, grippers, motors)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
Product category
Implantable Neuroprosthetics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Phantom Neuro will generate revenue through the sale of its Phantom X implantable neural interface system and associated prosthetic devices. The company is pursuing FDA regulatory approval to commercialize its technology for prosthetic limb control, targeting the medical device market for amputees and individuals with limb differences.

prnewswire.com
2Technology Licensing
TypeLicensing Royalties
Description

The company is exploring licensing its sensing platforms and movement data collection technology to robotics companies for human-robot collaboration applications.

phantomneuro.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface (MMI) system for prosthetic limb control. The system uses a subcutaneous implantable sensor that captures electrical signals directly from residual limb muscles and proprietary AI algorithms to decode movement intentions in real-time, enabling intuitive control of prosthetic hands, wrists, and robotic systems. Achieved 94% accuracy decoding 11 distinct hand and wrist movements in clinical studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 94% accuracy in decoding real-time gestures across 11 distinct hand and wrist movements
+3 more records
Product overview1 text field

Phantom Neuro offers a unified product platform anchored by the Phantom X muscle-machine interface system, designed to provide intuitive prosthetic limb control for amputees through an implantable sensor and AI-powered signal processing. The system achieved 94% accuracy in the ASCENT study and is undergoing first-in-human clinical evaluation through the CYBORG study in Australia. Supporting the core technology is a patient community registry platform for clinical trial recruitment and engagement. The company positions its technology for applications beyond prosthetics, including robotics and human augmentation, with a focus on defense and security markets.

Product and service2 records
1Phantom X
CategoryImplantable Neuroprosthetic System
Description

A muscle-machine interface (MMI) system consisting of a minimally invasive subcutaneous implantable sensor that captures electrical signals from residual limb muscles and proprietary AI-powered signal processing that decodes movement intent in real time. Provides amputees and individuals with limb difference with intuitive, multi-degree-of-freedom control of prosthetic hands, wrists, and robotic systems. For healthcare providers, prosthetists, and amputees.

2Phantom Neuro Community Registry
CategoryPatient Registry Platform
Description

A patient registry and community platform that connects individuals with limb loss and mobility challenges to clinical trial opportunities, providing updates on technology, research advancements, and patient stories. For amputees, caregivers, healthcare providers, and clinical research partners.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Clinical study site for CYBORG first-in-human Early Feasibility Study in Melbourne, Australia, performing surgical procedures for the Phantom X system implantation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Clinical partner providing prosthetic care for participants in the CYBORG first-in-human study in Melbourne, Australia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Clinical partner providing rehabilitation services for participants in the CYBORG first-in-human study in Melbourne, Australia.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global prosthetics incumbent and Phantom Neuro's Series A lead/board partner; broader portfolio of prosthetics and exoskeletons that could ultimately bundle or compete with Phantom Neuro's interface.

2CTRL Labs (Meta / Reality Labs)
TypeDirect peer
Description

Acquired by Meta, CTRL Labs developed wrist-worn EMG-based gesture decoding — the same muscle-signal decoding category Phantom Neuro pursues, though non-invasive. Phantom Neuro advisor Josh Duyan is former CSO.

TypeBroad incumbent
Description

High-profile implantable brain-computer interface company pursuing motor control and broader cognitive applications; competes for clinical, regulatory, and capital attention in the implantable neuro interface category.

TypeBroad incumbent
Description

Established global prosthetics and exoskeleton manufacturer with broad product lines; a key channel partner candidate and competitive incumbent in the amputee device market Phantom Neuro addresses.

TypeDirect peer
Description

Implantable neural interface company with motor-prosthetic applications; already an investor in Phantom Neuro, indicating direct category overlap in implantable neuroprosthetic control.

TypeDirect peer
Description

Direct neural interface competitor developing implanted brain-computer interfaces for motor control. Closely comparable in stage, regulatory pathway, and investor overlap (Synchron's founder/CEO Tom Oxley is a Phantom Neuro advisor).

TypeEmerging player
Description

BCI/neurotechnology company developing non-invasive wearable EMG/EEG products; an emerging player with adjacent neural-interface technology targeting similar rehabilitation and human-performance use cases.

TypeEmerging player
Description

Commercial-stage myoelectric orthotic device company; adjacent to Phantom Neuro's rehab/restoration focus, addressing upper-limb mobility impairment via EMG-driven wearable robotics.

TypeEmerging player
Description

Develops pattern-recognition and EMG-based prosthetic control technologies; comparable in targeting the upper-limb amputee segment with myoelectric signal decoding, though non-invasive.

TypeDirect peer
Description

Specialist in pattern-recognition control systems for myoelectric prosthetic limbs; directly competes for the same amputee customer segment using non-invasive EMG rather than an implantable interface.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phantom Neuro

Implantable Neuroprostheticsphantomneuro.com

Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface using proprietary AI and subcutaneous sensors to decode muscle signals for intuitive prosthetic limb control. The Austin-based company, founded in 2020, targets amputees and is pursuing FDA approval.

What Phantom Neuro does

Phantom Neuro is a clinical-stage neurotechnology company developing the Phantom X, a minimally invasive muscle-machine interface (MMI) that captures electrical signals from residual limb muscles through a subcutaneous implantable sensor and uses proprietary AI algorithms to decode movement intent in real-time for intuitive control of prosthetic limbs and robotic systems. Founded in 2020 by Connor Glass and headquartered in Austin, Texas, the platform has demonstrated 94% accuracy across 11 distinct hand and wrist movements in the ASCENT non-invasive validation study, with 10 minutes of calibration restoring up to 85% of hand and wrist functionality. The system is designed as a simple outpatient procedure—accessible to over 70,000 US practitioners—positioning it as a less invasive alternative to brain-computer interfaces for amputees.

The company is pursuing FDA regulatory approval and received both Breakthrough Device Designation and TAP Acceptance in 2025. Its first-in-human CYBORG Early Feasibility Study, approved in Australia in April 2026, will enroll up to 10 upper limb amputee participants over approximately 20 weeks at Cabrini Health in Melbourne, with prosthetic care provided by ProMotion Prosthetics and Enable Rehab. The Australian study is structured to support a future US FDA IDE submission and pivotal trial. Beyond prosthetics, Phantom Neuro is positioning its in-vivo movement data capture as a training asset for humanoid robotics and human-machine collaboration applications, with an active partnership with DARPA covering defense and exoskeleton use cases.

Phantom Neuro's business model is anchored on medical device hardware sales of the Phantom X system, with a secondary optionality around licensing its sensing platform and movement data to robotics companies. The company operates an enterprise medical device commercialization pathway—maintaining a community patient registry (registry.phantomneuro.com) for clinical trial recruitment, engaging in scientific publications, and leveraging its strategic partnership with Ottobock for distribution. Ottobock led the $19M Series A in April 2025 and holds a board seat, contributing global prosthetics commercialization expertise. The company has raised approximately $28M in total disclosed funding across seed, Series A, and non-dilutive DARPA support, with no commercial revenue to date.

Phantom Neuro firmographics

Firmographics
Name
Phantom Neuro
Legal name
Phantom Neuro Inc.
Website
https://phantomneuro.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface using proprietary AI and subcutaneous sensors to decode muscle signals for intuitive prosthetic limb control. The Austin-based company, founded in 2020, targets amputees and is pursuing FDA approval.
Ownership category
akta.pro rank

Phantom Neuro industry classification

Industry
Product category
Implantable Neuroprosthetics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHSADAIAC
Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS)
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
SECONDARYHDAAAIAL
Robot Hardware, Actuators & Components (sensors, grippers, motors)

Keywords

  • Implantable neural interface
  • Muscle-machine interface
  • Prosthetic limb control
  • Neural signal decoding
  • Robotic rehabilitation devices

Where Phantom Neuro is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Phantom Neuro business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: Phantom Neuro will generate revenue through the sale of its Phantom X implantable neural interface system and associated prosthetic devices. The company is pursuing FDA regulatory approval to commercialize its technology for prosthetic limb control, targeting the medical device market for amputees and individuals with limb differences.
  2. Technology Licensing: The company is exploring licensing its sensing platforms and movement data collection technology to robotics companies for human-robot collaboration applications.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Phantom Neuro product offering

Product offering

Core offering

Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface (MMI) system for prosthetic limb control. The system uses a subcutaneous implantable sensor that captures electrical signals directly from residual limb muscles and proprietary AI algorithms to decode movement intentions in real-time, enabling intuitive control of prosthetic hands, wrists, and robotic systems. Achieved 94% accuracy decoding 11 distinct hand and wrist movements in clinical studies.

Product overview

Phantom Neuro offers a unified product platform anchored by the Phantom X muscle-machine interface system, designed to provide intuitive prosthetic limb control for amputees through an implantable sensor and AI-powered signal processing. The system achieved 94% accuracy in the ASCENT study and is undergoing first-in-human clinical evaluation through the CYBORG study in Australia. Supporting the core technology is a patient community registry platform for clinical trial recruitment and engagement. The company positions its technology for applications beyond prosthetics, including robotics and human augmentation, with a focus on defense and security markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Phantom X A muscle-machine interface (MMI) system consisting of a minimally invasive subcutaneous implantable sensor that captures electrical signals from residual limb muscles and proprietary AI-powered signal processing that decodes movement intent in real time. Provides amputees and individuals with limb difference with intuitive, multi-degree-of-freedom control of prosthetic hands, wrists, and robotic systems. For healthcare providers, prosthetists, and amputees.
  • Phantom Neuro Community Registry A patient registry and community platform that connects individuals with limb loss and mobility challenges to clinical trial opportunities, providing updates on technology, research advancements, and patient stories. For amputees, caregivers, healthcare providers, and clinical research partners.

Quantifiable outcome

  • 94% accuracy in decoding real-time gestures across 11 distinct hand and wrist movements
  • +3 more outcomes

Companies that use Phantom Neuro

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Phantom Neuro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Phantom Neuro partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Cabrini HealthcoreStrategic or Co-development Partner · 15 April 2026Clinical study site for CYBORG first-in-human Early Feasibility Study in Melbourne, Australia, performing surgical procedures for the Phantom X system implantation.
  • ProMotion ProstheticscoreStrategic or Co-development Partner · 15 April 2026Clinical partner providing prosthetic care for participants in the CYBORG first-in-human study in Melbourne, Australia.
  • Enable RehabcoreStrategic or Co-development Partner · 15 April 2026Clinical partner providing rehabilitation services for participants in the CYBORG first-in-human study in Melbourne, Australia.

Scale indicators15 records

Recent moves5 records

Expansion highlights6 records

Phantom Neuro competitors and assessment

Company assessment

Broad incumbents

  • Ottobock: Global prosthetics incumbent and Phantom Neuro's Series A lead/board partner; broader portfolio of prosthetics and exoskeletons that could ultimately bundle or compete with Phantom Neuro's interface.
  • Neuralink: High-profile implantable brain-computer interface company pursuing motor control and broader cognitive applications; competes for clinical, regulatory, and capital attention in the implantable neuro interface category.
  • Össur: Established global prosthetics and exoskeleton manufacturer with broad product lines; a key channel partner candidate and competitive incumbent in the amputee device market Phantom Neuro addresses.

Direct peers

  • CTRL Labs (Meta / Reality Labs): Acquired by Meta, CTRL Labs developed wrist-worn EMG-based gesture decoding — the same muscle-signal decoding category Phantom Neuro pursues, though non-invasive. Phantom Neuro advisor Josh Duyan is former CSO.
  • Blackrock Neurotech: Implantable neural interface company with motor-prosthetic applications; already an investor in Phantom Neuro, indicating direct category overlap in implantable neuroprosthetic control.
  • Synchron: Direct neural interface competitor developing implanted brain-computer interfaces for motor control. Closely comparable in stage, regulatory pathway, and investor overlap (Synchron's founder/CEO Tom Oxley is a Phantom Neuro advisor).
  • Coapt: Specialist in pattern-recognition control systems for myoelectric prosthetic limbs; directly competes for the same amputee customer segment using non-invasive EMG rather than an implantable interface.

Emerging players

  • BrainCo: BCI/neurotechnology company developing non-invasive wearable EMG/EEG products; an emerging player with adjacent neural-interface technology targeting similar rehabilitation and human-performance use cases.
  • Myomo: Commercial-stage myoelectric orthotic device company; adjacent to Phantom Neuro's rehab/restoration focus, addressing upper-limb mobility impairment via EMG-driven wearable robotics.
  • Infinite Biomedical Technologies: Develops pattern-recognition and EMG-based prosthetic control technologies; comparable in targeting the upper-limb amputee segment with myoelectric signal decoding, though non-invasive.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Phantom Neuro social profiles

Digital presence

Phantom Neuro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phantom Neuro leadership team

Management profile

Number of profiles

Profiles18 records

Phantom Neuro funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phantom Neuro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phantom Neuro

What does Phantom Neuro do?

Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface (MMI) system for prosthetic limb control. The system uses a subcutaneous implantable sensor that captures electrical signals directly from residual limb muscles and proprietary AI algorithms to decode movement intentions in real-time, enabling intuitive control of prosthetic hands, wrists, and robotic systems. Achieved 94% accuracy decoding 11 distinct hand and wrist movements in clinical studies.

Is Phantom Neuro a public or private company?

Phantom Neuro is a private company. It is classified as venture growth investor backed and is currently operating.

When was Phantom Neuro founded?

Phantom Neuro was founded in 2020. It employs 11 to 50 people.

Where is Phantom Neuro based?

Phantom Neuro is headquartered in Austin, United States, in the North America region.

How does Phantom Neuro make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are technology Licensing.

Who are Phantom Neuro's main competitors?

Broad incumbents on record are Ottobock, Neuralink and Össur. Direct peers are CTRL Labs (Meta / Reality Labs), Blackrock Neurotech, Synchron and Coapt. Emerging players are BrainCo, Myomo and Infinite Biomedical Technologies.

Does Phantom Neuro have an API?

No public API is recorded for Phantom Neuro.

What industry is Phantom Neuro in?

Phantom Neuro's product category is Implantable Neuroprosthetics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HSADAIAC, Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS). Its NAICS code is 334510.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MobiHealthNewsPhantom Neuro implants first humans with its muscle-machine interfacePhantom Neuro implanted its Phantom X device in humans during its CYBORG study in Australia, with procedures lasting about an hour and no general anesthesia. The investigational device translates residual limb muscle signals into commands for prosthetics, and further evaluation is needed for safety and effectiveness.ForbesSmart Hands, Human Touch: Neurotech Tightens Grip On Robotics MarketPhantom Neuro and BIOS implanted neural interfaces in human participants to control smart prosthetic arms, with Phantom's first implantation in Australia and BIOS's trial participant demonstrating hand sensation. Both companies target upper-limb prosthetics as a first market, with commercial launch expected by 2028.PR NewswirePhantom Neuro Implants Neural Interface in Humans for the First TimePhantom Neuro implanted its Phantom X neural interface in the first human participants with upper limb loss at Cabrini Health in Melbourne, Australia. The outpatient procedures lasted about an hour each without general anesthesia, marking the first implantation of the company's sensor. The CYBORG study is ongoing to evaluate safety and performance.PR NewswireNeurotech Pioneer Phantom Neuro Joins Amputee Coalition's Partnership ProgramPhantom Neuro, a neurotechnology firm developing prosthetic control interfaces, joined the Amputee Coalition's Partnership Program. The coalition serves over 5.6 million Americans with limb loss or difference. Phantom Neuro's Phantom X interface is being studied for intuitive prosthetic control.Medical Device NetworkPhantom Neuro secures approval for muscle-machine interface trialPhantom Neuro secured approval to begin its first-in-human trial of the Phantom X muscle-machine interface in Australia. The CYBORG study will involve up to ten amputee subjects in Melbourne, assessing efficacy, safety, and usability. The trial aims to validate real-time prosthetic control via a minimally invasive implant.PR NewswirePhantom Neuro Receives Approval for First-In-Human Clinical StudyPhantom Neuro has received approval to conduct its first-in-human Early Feasibility Study (CYBORG) of the Phantom X muscle-machine interface system in Australia, marking the company's transition from preclinical validation to human implantation. The study will enroll up to 10 upper limb amputee participants in Melbourne, with surgical procedures at Cabrini Health and prosthetic care provided by ProMotion Prosthetics and Enable Rehab. Results from the approximately 20-week study will support Phantom Neuro's future U.S. FDA IDE submission and pivotal trial.openPR.comAnalysis of Segments and Major Growth Areas in the Bionic Devices MarketThe global bionic devices market is projected to reach $8.76 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%, driven by advancements in neural interface technology and increasing demand for lifelike prosthetics. In February 2024, Hanger Inc. acquired Fillauer Companies Inc. to expand its prosthetic and orthotic portfolio, with financial terms undisclosed. In April 2025, German prosthetics manufacturer Ottobock led a $19 million Series A funding round for neurotechnology firm Phantom Neuro, which is developing the Phantom X interface with 94% accuracy for decoding hand and wrist movements.TipranksPhantom Neuro Showcases Minimally Invasive Neurotech Interface for Prosthetics and ExoskeletonsPhantom Neuro presented its Phantom X system at The Montgomery Summit, a minimally invasive neurotechnology interface designed for control of robotic prosthetics and exoskeletons. The company aims to expand clinical deployment and is building a pipeline of human studies to support future regulatory and commercial milestones.KEYEAustin Startup Turns Thought Into Motion for AmputeesPhantom Neuro, an Austin-based startup, has developed a prosthetic limb control system that reads electrical signals from muscles through a minimally invasive implant placed just under the skin, allowing amputees to control robotic limbs naturally without brain surgery. The technology, which interprets the body's intent to move directly from muscle impulses in the forearm, is described by founder and CEO Connor Glass as nearly complete and ready for human use. Clinical trials are planned to begin this year in Australia, with the goal of demonstrating the system's capabilities for users like Alex Smith, who lost his arm in a boating accident and can now control hand and wrist movements simply by thinking about them.